ERBB2 and neoplasm: Park et al. [28] showed that HER2-targeted doxorubicin liposomes with internalizing ligand exhibited a significant increase in anti-tumour efficacy and reduced systemic toxicity compared with the non-targeted doxorubicin liposomes.